🧾 What This Document Is

This is Rocket Pharmaceuticals' definitive proxy statement (DEF 14A). It's an official invitation and information packet for shareholders ahead of the 2026 Annual Meeting on May 20, 2026. The purpose is to let shareholders vote on key company decisions.
👉 Why it matters: If you own RCKT stock, this tells you what you're voting on and gives you crucial details about the company's leadership and finances.

🏢 What The Company Does

In simple terms, Rocket Pharmaceuticals is a late-stage biotech company developing gene therapies for rare, often fatal genetic diseases. They focus on inherited heart disorders and aim to deliver one-time, potentially curative treatments.
👉 Why it matters: This is a high-risk, high-reward field. The company's future depends on clinical trials and regulatory approvals, making governance and financial health critical.

📅 Meeting Logistics & Key Dates

The Annual Meeting will be held virtually on May 20, 2026, at 9:00 a.m. ET at www.virtualshareholdermeeting.com/RCKT2026.

Record Date: March 24, 2026. Only shareholders on this date can vote.
How to Vote: You can vote online, by phone, or by mail before the meeting. Your last vote counts.
👉 Why it matters: You need to actively participate to have a say. The virtual format aims to increase accessibility.

🗳️ The Four Proposals You're Voting On

The Board recommends voting "FOR" on all four proposals.

Elect 7 Directors: Vote for the board members who will oversee the company.
Ratify Auditor: Approve EisnerAmper LLP as the independent accounting firm for 2026.
"Say-on-Pay": An advisory (non-binding) vote on executive compensation.
Stock Option Exchange Program: A key proposal to exchange certain employee stock options.
👉 Why it matters: Proposal 4 is especially significant. It's a "do-over" for employee stock options, likely because the current stock price is below the options' strike price. This can be crucial for retaining talent in a tough biotech market.

👥 Board & Governance Changes

Two Directors are Leaving: Dr. Elisabeth Björk and Mr. Piratip Pratumsuwan will not stand for re-election.
New Chairman: If elected, Dr. Peter Fong (Partner at RTW) will become Chairman, replacing Dr. Roderick Wong, who will stay on the board.
Executive Team: The CEO is Dr. Gaurav Shah. Recent hires include a new Chief Commercial Officer and Chief Medical Officer, signaling a push toward potential product launches.
👉 Why it matters: Leadership transitions and a refreshed board indicate strategic evolution. RTW (a major investor) has a strong influence.

💰 Executive Compensation (Proposal 3)

The "Say-on-Pay" vote lets shareholders express opinion on executive pay. The 2025 Summary Compensation Table shows CEO Gaurav Shah's total compensation was $8.7 million, primarily in stock awards.
👉 Why it matters: While advisory, a low approval vote pressures the board to adjust compensation practices. It's a check on whether pay aligns with company performance.

💸 The Stock Option Exchange Program (Proposal 4)

This is the most detailed proposal. It allows eligible employees to exchange "underwater" stock options (those with a strike price higher than the current stock price) for new options with a lower strike price.

Goal: Retain and motivate employees whose existing options have lost perceived value.
Why now: Reflects the challenging biotech market and Rocket's depressed stock price.
👉 Why it matters: This is a significant retention tool. If approved, it helps keep key scientists and executives but dilutes existing shareholders.

🔮 What's Next & Company Outlook

Strategic Focus: The company highlights its integrated R&D and manufacturing capabilities.
Upcoming Catalyst: The annual meeting and the outcome of the option exchange vote.
General Context: The biotech sector is facing valuation pressures, making retention and cash management vital.
👉 Why it matters: The company is in a "late-stage" phase, meaning high spending before potential revenue. Shareholder support on governance and retention tools is crucial for navigating this period.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

Focused on high-need rare diseases with large market potential.
Experienced leadership and board with big-pharma backgrounds.
Advanced manufacturing setup (a key competitive advantage).

⚠️ Risks:

Pre-revenue, with high cash burn.
Clinical trial and regulatory approval risks are inherent.
Stock price volatility and potential shareholder dilution from programs like the option exchange.

🧠 The Analogy

Rocket Pharmaceuticals is like a high-performance rocket in a testing phase. The company has built a powerful engine (gene therapy platform) and assembled a skilled crew (the board and executives). But it's still on the launchpad, burning fuel (cash) and needing all hands focused on the mission. The stock option exchange is like retraining the crew with new instruments because some original controls aren't responding—critical for keeping the team aligned for launch, but it slightly changes the ownership of the rocket.

🧩 Final Takeaway

This proxy is about governance and morale during a challenging market. Shareholders are being asked to approve a leadership transition and a significant employee retention plan (the option exchange). The votes will signal confidence in the current strategy as the company navigates the expensive and risky late stages of drug development.

ROCKET PHARMACEUTICALS, INC. — DEF 14A Filing